This document aims to support public health preparedness planning and response activities on the safe handling of bodies of deceased persons with suspected or confirmed COVID-19: at the site of death, during transport, storage and preparation before burial/cremation, and during burial/cremation.
22 février 2020 Addis-Abeba, Éthiopie
Available translations: Albanian, Armenian, Azerbaijani, Bosnian, Bulgarian, Croatian, Czech, Danish, French, Georgian, German, Greek, Hungarian, Italian, Lithuanian, Macedonian, Polish, Romanian, Russian, Serbian, Slovenian, Spanish, Turkish, Ukrainian
Go to the website: https://www.cö.int/en/web.../cpt/-/covid-19-council-of-europe-anti-torture-committee-issüs-statement-of-principles-relating-to-the-treatment-of-persons-deprived-of-their-liberty-
more
O presente documento fornece orientações aos Estados-Membros da União Africana sobre as acções a empreender para garantir que continuam a satisfazer todos os requisitos em matéria de saúde
necessidades dos seus cidadãos, de acordo com a realização dos objectivos da Estratégia de Saúde p...ara África 2016 - 2030.
more
The speed of developing diagnostics for SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has been quite remarkable. Diagnostics have focused on nucleic acid amplification testing (NAAT) to identify infected individuals in acute-phase disease for timely implementation of mitiga...tion strategies and case management. More and more immunodiagnostics, mostly rapid diagnostic tests, are being made available as an alternative to NAATs. This type of test can be used out-of-laboratory conditions at large scale.
more
Os medicamentos tradicionais à base de plantas ou fitomedicamentos desempenham um papel significativo na gestão de doenças em África e são amplamente utilizados como medicamentos alternativos. Por conseguinte, é importante avaliar tanto a segurança como a eficácia destes bens botânicos ind...genas na medicina antes de endossar a sua utilização pela comunidade médica e pelo público.
more
A Estratégia Conjunta Continental Africana para a COVID-19 é sustentada pela necessidade de limitar a transmissão, prevenir mortes e reduzir os danos associados. A participação das nações africanas em ensaios clínicos é um passo essencial para garantir que sejam gerados dados suficientes so...bre a segurança e eficácia dos candidatos a vacinas mais promissores entre as populações da região.
Embora a actual actividade de ensaios clínicos COVID-19 no continente seja limitada, a África tem uma experiência e capacidades substanciais para conduzir ensaios clínicos de vacinas preventivas numa série de doenças, e muitas organizações no continente estão a trabalhar incansavelmente para ajudar a preparar ensaios adicionais sobre potenciais vacinas COVID-19.
Disponível em inglês, francês e português
more
The global pandemic has highlighted fragility in international supply chains and the dependency of many African countries on imported personal protective equipment (PPE). Market pressures have also increased prices for imported supplies and put additional pressure on areas with limited resources for... procurement. There is an urgent operational need to develop the domestic capacity to supply PPE from within the African continent. There is huge variation in Member
States industrial manufacturing capacity and the regulatory and testing capacity of government agencies at present. Growing number of companies, including micro- and small-medium enterprises, have responded by repurposing, albeit temporarily, to manufacture an assortment of PPEs. This workshop aims to bring together government representatives, industry, and subject matter experts on material testing and standards to promote the development of domestic production of safe and effective PPE made in Africa.
more
In an effort to limit transmission and achieve pandemic control on the continent, Africa CDC is proposing the following measures to be taken by all Member States:
Remain vigilant
Countries should adapt or adopt best practices, strategies, guidelines and recommendations proposed by the Africa CDC... and World Health Organization (WHO), aimed at limiting transmission. Measures taken should strike a balance between saving lives and minimizing the impact of the pandemic on the economy and social wellbeing of citizens.
more
Compte tenu des lacunes en matière d'infrastructures et de ressources, il convient d'envisager de recourir à la technologie pour la gestion à distance des soins de santé dispensés aux patients pendant cette période. Comme on peut le constater, même les pays disposant d'infrastructures et de r...essources de soins de santé plus avancées ont eu du mal à traiter les patients atteints de COVID-19 ou non pendant cette pandémie.
more
ASLM in collaboration with the Africa Centres for Disease Control and Prevention, and in partnership with the Clinton Health Access Initiative, Amref and Last Mile Health present the Quality Assurance Framework for SARS-CoV-2 Antigen Rapid Testing for Diagnosis of COVID-19. This framework aims to pr...ovide general technical guidance to African Union Members States on the rollout, establishment, implementation, monitoring, and evaluation of SARS-CoV-2 Ag RDT interventions so as to effectively and efficiently detect, control and minimise errors in the performance of COVID-19 laboratory testing processes. It describes the core components for quality assurance, resources mobilisation and advocacy for scale up, monitoring, evaluation, learning and accountability for SARS-CoV-2 implementation.
more
Formation d'orientation pendant 2 jours25 Juin 2020
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ...de la COVID-19 par le public dans les États membres de l’Union africaine. Actuellement, il n’y a : 1. Aucune preuve scientifique provenant d’études précliniques sur l’effet thérapeutique de l’ivermectine pour le traitement de COVID-19 2. Aucune preuve de son efficacité clinique pour la prise en charge de patients présentant une COVID-19 asymptomatique, légère, modérée ou sévère 3. Aucune donnée de sécurité concernant l’utilisation de l’ivermectine pour la COVID-19 dans la majorité des études publié
more
Mars 2020. Recommendations selon les differentes phases
Press Release 14 June 2021